Observed improvements were similar between adults with EOT2D and later-onset T2DM, and there were no clear differences in the rates of adverse events between cohorts
It's about them being entirely different tools designed for different scientific questions
By leveraging Xevants data analytics and Ivm Healths clinical expertise, we are confident in delivering a program that sets a new standard in corporate wellness. The program will be available starting August 1
16 17 18 Newly emerging indications for GLP-1 medicationsincluding heart disease, metabolic liver disease, peripheral artery disease, Alzheimers/dementia risk, and even alcohol and substance use disorders, as highlighted in a 2025 study in JAMA 19 suggest these drugs may soon play a much broader role in medicine than just treating diabetes or obesity
That's a meaningful distinction for how we'll eventually discuss switching
Clinical oversight affects pricing as well